This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements and substitutes and active wound repair modulators market. Major topics covered by this report include an overview of the healthcare markets of France, Germany, Italy, Spain, and the United Kingdom; an overview of clinical issues in wound management; skin replacement and substitutes including allografts, autografts, xenografts, amniotic membranes, and autologous and tissue-engineered skin replacements and substitutes (e.g., epidermal, dermal, and composite bilayer skin equivalents); and active wound repair modulators including topical antimicrobials, growth factors, gene therapy agents, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, neuropeptides, and stem cells.
EXECUTIVE SUMMARY i. Clinical Issues in Wound Management ii. Skin Replacements and Substitutes a. Allografts b. Autografts c. Xenografts d. Amniotic Membranes e. Skin Equivalents f. Skin Replacements and Substitutes, Market Analysis iii. Active Wound Repair Modulators a. Topical Antimicrobial Products b. Growth Factors c. Other Active Wound Repair Modulators d. Active Wound Repair Modulators, Market Analysis iv. Combined Market Analysis a. Market Drivers b. Market Limiters c. Combined Market Forecast Exhibit ES-1: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit ES-2: Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013 Exhibit ES-3: Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013 1. EUROPEAN HEALTHCARE MARKETS 1.1 The European Union 1.1.1 A Common Currency 1.1.2 Regulatory Policies 1.1.3 Reimbursement 1.1.4 Healthcare Spending 1.2 Selected European National Healthcare Profiles 1.2.1 France 188.8.131.52 Healthcare Organization and Reform 184.108.40.206 Hospital Services 220.127.116.11 Medical Device Reimbursement 1.2.2 Germany 18.104.22.168 Healthcare Organization and Reform 22.214.171.124 Hospital Services 126.96.36.199 Medical Device Reimbursement 1.2.3 Italy 188.8.131.52 Healthcare Organization and Reform 184.108.40.206 Hospital Services 220.127.116.11 Medical Device Reimbursement 1.2.4 Spain 18.104.22.168 Healthcare Organization and Reform 22.214.171.124 Hospital Services 126.96.36.199 Medical Device Reimbursement 1.2.5 United Kingdom 188.8.131.52 Healthcare Organization and Reform 184.108.40.206 Hospital Services 220.127.116.11 Medical Device Reimbursement Exhibit 1-1: European Union, Medical Devices Risk Classification System Exhibit 1-2: European Union Population Statistics Comparison for the Years 1999, 2009, and 2019 Exhibit 1-3: France, Selected National Healthcare Statistics Exhibit 1-4: Germany, Selected National Healthcare Statistics Exhibit 1-5: Italy, Selected National Healthcare Statistics Exhibit 1-6: Spain, Selected National Healthcare Statistics Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics 2. CLINICAL ISSUES IN WOUND MANAGEMENT 2.1 Physiology of Wound Closure 2.1.1 Layers of the Skin and Supporting Structures 18.104.22.168 Epidermis 22.214.171.124 Dermis 126.96.36.199 Subcutaneous Tissue 188.8.131.52 Fascia 184.108.40.206 Muscle 220.127.116.11 Bone 2.1.2 Wound Closure Process 18.104.22.168 Hemostasis 22.214.171.124 Inflammation 126.96.36.199 Proliferation 188.8.131.52 Remodeling Phase 2.2 Factors Affecting Wound Closure 2.2.1 Extrinsic Factors 184.108.40.206 Desiccation 220.127.116.11 Hydration 18.104.22.168 Infection 22.214.171.124 Maceration 126.96.36.199 Medication and Other Treatment Modalities 188.8.131.52 Necrotic Tissue and Debris 184.108.40.206 Oxygenation 220.127.116.11 Stress 18.104.22.168 Temperature 22.214.171.124 Wound Creation and Depth 126.96.36.199 Wound Closure Techniques 188.8.131.52 Other Extrinsic Factors 2.2.2 Intrinsic Factors 184.108.40.206 Body Build 220.127.116.11 Chronic Illness and Age 18.104.22.168 Nutrition 2.2.3 Complications of Wound Healing 22.214.171.124 Bleeding 126.96.36.199 Scarring 2.3 Major Wound Types 2.3.1 Amputation 2.3.2 Arterial Ulcers 2.3.3 Burns 2.3.4 Diabetic Ulcers 2.3.5 Pressure Ulcers 2.3.6 Surgical Wounds 2.3.7 Traumatic Wounds 2.3.8 Venous Ulcers Exhibit 2-1: The Skin's Layers and Supporting Structures Exhibit 2-2: Phases of the Wound Closure Process Exhibit 2-3: Extrinsic and Intrinsic Factors Affecting Wound Closure Exhibit 2-4: Major Wound Types, by Cause Exhibit 2-5: Stages of Burn Wounds Exhibit 2-6: Stages of Pressure Ulcers Exhibit 2-7: 2008, Europe, Surgical Procedure Volumes, by Type 3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET 3.1 Allografts 3.2 Autografts 3.3 Xenografts 3.4 Amniotic Membranes 3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes 3.5.1 Epidermal Equivalents 3.5.2 Dermal Equivalents 3.5.3 Composite Bilayer Skin Equivalents 3.6 Skin Substitute Products under Development 3.6.1 Advanced BioHealing 3.6.2 Healthpoint/DFB Pharmaceuticals 3.6.3 Organogenesis 3.6.4 Dr. Suwelack Skin & Health Care 3.7 Market Analysis 3.8 Competitive Analysis Exhibit 3-1: Advantages and Disadvantages of Allografts Exhibit 3-2: 2010, Selected Epidermal Equivalent Skin Substitutes Exhibit 3-3: 2010, Selected Dermal Equivalent Skin Substitutes Exhibit 3-4: 2010, Selected Composite Bilayer Equivalent Skin Substitutes Exhibit 3-5: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit 3-6: 2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier 4. ACTIVE WOUND REPAIR MODULATORS MARKET 4.1 Topical Antimicrobials 4.1.1 Products 4.1.2 Market Analysis 4.1.3 Competitive Analysis 4.2 Growth Factors 4.2.1 Classification of Growth Factors 188.8.131.52 Fibroblast Growth Factors 184.108.40.206 Transforming Growth Factors 220.127.116.11 Epidermal Growth Factors 18.104.22.168 Platelet-Derived Growth Factors 22.214.171.124 Insulin-Like Growth Factors 126.96.36.199 Keratinocyte Growth Factors 188.8.131.52 Vascular Endothelial Growth Factors 184.108.40.206 Autologous Growth Factors 220.127.116.11.1 Arteriocyte Medical Systems 18.104.22.168.2 Cytomedix 22.214.171.124.3 Harvest Technologies 126.96.36.199 Angiogenic Growth Factors 4.2.2 Products 4.2.3 Market Analysis 4.3 Gene Therapy Agents 4.4 Other Active Wound Repair Modulators 4.4.1 Antibiotics and Anti-Infectives 188.8.131.52 Basilea Pharmaceutica 184.108.40.206 Cerexa/Forest Laboratories 220.127.116.11 Cubist Pharmaceuticals 18.104.22.168 Helix BioMedix 22.214.171.124 Theravance 4.4.2 Hormones 4.4.3 Matrix Metalloproteinase Enzyme Inhibitors 126.96.36.199 Dermagenics/Greystone Pharmaceuticals 188.8.131.52 Smith & Nephew 184.108.40.206 Systagenix Wound Management 4.4.4 Neuropeptides in Diabetic Wounds 4.4.5 Stem Cells 4.4.6 Other Products 220.127.116.11 Kingfisher Healthcare 18.104.22.168 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology 22.214.171.124 RegeneRx Biopharmaceuticals Exhibit 4-1: 2010, Selected Topical Antimicrobial Products Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013 Exhibit 4-3: 2009, Europe, Topical Antimicrobial Products, Share by Supplier Exhibit 4-4: 2010, Selected Growth Factors in Development for Wound Healing Applications Exhibit 4-5: 2010, Selected Angiogenic Growth Factors Exhibit 4-6: Europe, Growth Factors Used in Wound Healing Applications, Market Forecast, by Country, 2008-2013 5. COMPANY PROFILES 5.1 Advanced BioHealing, Inc. 5.2 Cook Biotech, Inc./Cook Group, Inc. 5.3 Cytomedix, Inc. 5.4 Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc. 5.5 GlaxoSmithKline PLC 5.6 Integra LifeSciences Corporation 5.7 LEO Pharma AS/LEO Foundation 5.8 sanofi-aventis 5.9 Smith & Nephew PLC 5.10 Systagenix Wound Management LTD APPENDIX: COMPANY LISTING